Replimune

Replimune is developing novel, proprietary oncolytic immunotherapies intended to improve both the direct anti-tumor effects of selective virus replication and the potency of the immune response to the tumor antigens released.
Type
Private
HQ
Milton, GB
Founded
2015
Replimune was founded in 2015 and is headquartered in Milton, GB

Replimune Office Locations

Replimune has offices in Milton and Woburn
Milton, GB (HQ)
69 Park Dr
Woburn, US
18 Commerce Way

Replimune Financials and Metrics

Summary Metrics

Founding Date

2015

Total Funding

$30 m

Latest funding size

$30 m

Time since last funding

about 2 years

Investors

Replimune's latest funding round in September 2015 was reported to be $30 m. In total, Replimune has raised $30 m

Replimune Financials

GBP

Net income (FY, 2017)

(3.3 m)

EBITDA (FY, 2017)

(4.3 m)

EBIT (FY, 2017)

(4.4 m)

Cash (31-Mar-2017)

15.9 m
GBPFY, 2016FY, 2017

EBITDA

(671.3 k)(4.3 m)

EBIT

(689.8 k)(4.4 m)

Pre tax profit

(679.4 k)(4.4 m)

Income tax expense

201 k1.1 m
GBPFY, 2016FY, 2017

Cash

9.7 m15.9 m

Current Assets

10.6 m20.3 m

PP&E

115.6 k202.4 k

Total Assets

10.8 m20.5 m
    GBPFY, 2016FY, 2017

    Net Income

    (478.4 k)(3.3 m)

    Cash From Operating Activities

    (1.4 m)(6 m)

    Cash From Financing Activities

    11 m12.3 m

    Net Change in Cash

    9.4 m6.1 m
      Y, 2017

      Financial Leverage

      1 x
      Show all financial metrics

      Replimune's Web-traffic and Trends

      Replimune Company Life and Culture

      You may also be interested in